The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Meta-analysis: β-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure
Abstract
BACKGROUND: Guidelines recommend that patients with heart failure receive beta-blockers in doses used in the trials that have proven their efficacy. Although the adverse effects of beta-blockade are dose-related, it is unclear whether the benefits are. PURPOSE: To determine whether the survival benefits of beta-blockade in heart failure are associated with the magnitude of heart rate reduction or the beta-blocker dose. DATA SOURCES: MEDLINE, EMBASE, CINAHL, SIGLE, Web of Science, and the Cochrane Central Register of Controlled Trials, supplemented by hand-searches of bibliographies. STUDY SELECTION: Randomized, placebo-controlled heart failure trials that reported all-cause mortality. DATA EXTRACTION: Two reviewers independently extracted data on study characteristics, beta-blocker dosing and heart rate reduction, and death. DATA SYNTHESIS: The mean left ventricular ejection fraction in the 23 beta-blocker trials ranged from 0.17 to 0.36, and more than 95% of the 19 209 patients had systolic dysfunction. The overall risk ratio for death was 0.76 (95% CI, 0.68 to 0.84); however, heterogeneity testing revealed moderate heterogeneity among trials (I (2) = 30%), which was associated with the magnitude of heart rate reduction achieved within each trial (P for meta-regression = 0.006). For every heart rate reduction of 5 beats/min with beta-blocker treatment, a commensurate 18% reduction (CI, 6% to 29%) in the risk for death occurred. No significant relationship between all-cause mortality and beta-blocker dosing was observed (risk ratio for death, 0.74 [CI, 0.64 to 0.86]) in high-dose beta-blocker trials vs. 0.78 [CI, 0.63 to 0.96] in low-dose beta-blocker trials; P for meta-regression = 0.69). LIMITATIONS: The analysis is based on aggregate data and resting heart rates. Few patients in these trials had bradycardia or diastolic dysfunction at baseline. CONCLUSION: The magnitude of heart rate reduction is statistically significantly associated with the survival benefit of beta-blockers in heart failure, whereas the dose of beta-blocker is not.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
(1999) · The Lancet · doi:10.1016/s0140-6736(98)11181-9 · Cited by 4,929
The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
Packer, M., Bristow, M. R., Cohn, J. N., Colucci, W. S., Fowler, M. B., Gilbert, E. M., & Shusterman, N. H. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605233342101 · Cited by 4,649
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
How should meta‐regression analyses be undertaken and interpreted?
Thompson, S. G., & Higgins, J. P. T. (2002) · Statistics in Medicine · doi:10.1002/sim.1187 · Cited by 3,026
Identifiability and exchangeability for direct and indirect effects
Robins, J. M., & Greenland, S. (1992) · Epidemiology · doi:10.1097/00001648-199203000-00013 · Cited by 1,793
Flather, M. D., Shibata, M. C., Coats, A. J. S., Van Veldhuisen, D. J., Parkhomenko, A., Borbola, J., Cohen-Solal, A., Dumitrascu, D., Ferrari, R., Lechat, P., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi115 · Cited by 1,655
Hjalmarson, Å., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein, F., Kjekshus, J., Wikstrand, J., El Allaf, D., Vítovec, J., Aldershvile, J., et al. (2000) · JAMA · doi:10.1001/jama.283.10.1295 · Cited by 1,399
Bristow, M. R., Gilbert, E. M., Abraham, W. T., Adams, K. F., Fowler, M. B., Hershberger, R. E., Kubo, S. H., Narahara, K. A., Ingersoll, H., Krueger, S., et al. (1996) · Circulation · doi:10.1161/01.cir.94.11.2807 · Cited by 1,303
Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy
Waagstein, F., Hjalmarson, A., Swedberg, K., Bristow, M. R., Gilbert, E. M., Camerini, F., Fowler, M. B., Silver, M. A., Johnson, M. R., & Goss, F. G. (1993) · The Lancet · doi:10.1016/0140-6736(93)92930-r · Cited by 1,234
Research works printed but not linked: 3
- 10.1093/eurheartj/sum031 · DOI
- 10.1088/0031-9155/21/2/001 · doi:10.1088/0031-9155/21/2/001
- 10.1093/eurheartj/ehi386 · DOI · Paper page
Cited by
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Swedberg, K., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61198-1 · Cited by 2,563
Böhm, M., Swedberg, K., Komajda, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61259-7 · Cited by 1,099
Myocardial Iodine-123 Meta-Iodobenzylguanidine Imaging and Cardiac Events in Heart Failure
Jacobson, A. F., Senior, R., Cerqueira, M. D., Wong, N. D., Thomas, G. S., Lopez, V. A., Agostini, D., Weiland, F., Chandna, H., & Narula, J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.014 · Cited by 871
Maddox, T. M., Januzzi, J. L., Allen, L. A., Breathett, K., Butler, J., Davis, L. L., Fonarow, G. C., Ibrahim, N. E., Lindenfeld, J., Masoudi, F. A., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.022 · Cited by 842
Ezekowitz, J. A., O'Meara, E., McDonald, M. A., Abrams, H., Chan, M., Ducharme, A., Giannetti, N., Grzeslo, A., Hamilton, P. G., Heckman, G. A., et al. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.08.022 · Cited by 676
Self-citation
Metadata
- Authors
- McAlister, F. A., Wiebe, N., Ezekowitz, J. A., Leung, A. A., & Armstrong, P. W.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2009-06-02
- Volume
- 150
- Issue
- 11
- Pages
- 784-794
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W1985431801
- Cited by
- 479
- References
- 54
- FWCI
- 19.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Meta-analysis: β-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure. https://app.cochat.ai/papers/10.7326/0003-4819-150-11-200906020-00006
- The paper
- McAlister, F. A., Wiebe, N., Ezekowitz, J. A., Leung, A. A., & Armstrong, P. W. (2009). Meta-analysis: β-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-150-11-200906020-00006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.